Gianantonio Rosti

16.7k total citations · 1 hit paper
215 papers, 6.6k citations indexed

About

Gianantonio Rosti is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Gianantonio Rosti has authored 215 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 194 papers in Hematology, 154 papers in Genetics and 81 papers in Rheumatology. Recurrent topics in Gianantonio Rosti's work include Chronic Myeloid Leukemia Treatments (174 papers), Chronic Lymphocytic Leukemia Research (145 papers) and Eosinophilic Disorders and Syndromes (81 papers). Gianantonio Rosti is often cited by papers focused on Chronic Myeloid Leukemia Treatments (174 papers), Chronic Lymphocytic Leukemia Research (145 papers) and Eosinophilic Disorders and Syndromes (81 papers). Gianantonio Rosti collaborates with scholars based in Italy, Germany and United States. Gianantonio Rosti's co-authors include Michele Baccarani, Giovanni Martinelli, Fausto Castagnetti, Simona Soverini, Giuseppe Saglio, Andreas Hochhaus, Gabriele Gugliotta, Fabrizio Pane, Hagop M. Kantarjian and Marilina Amabile and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Gianantonio Rosti

207 papers receiving 6.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

2016 330 citations Michele Baccarani, Massimo Breccia et al. Leukemia profile →

Peers

Countries citing papers authored by Gianantonio Rosti

Since Specialization

Citations

This map shows the geographic impact of Gianantonio Rosti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gianantonio Rosti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gianantonio Rosti more than expected).

Fields of papers citing papers by Gianantonio Rosti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gianantonio Rosti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gianantonio Rosti. The network helps show where Gianantonio Rosti may publish in the future.

Co-authorship network of co-authors of Gianantonio Rosti

This figure shows the co-authorship network connecting the top 25 collaborators of Gianantonio Rosti. A scholar is included among the top collaborators of Gianantonio Rosti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gianantonio Rosti. Gianantonio Rosti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study 2024 ·Leukemia Research ·B. Douglas Smith, Tim H. Brümmendorf, Gail J. Roboz, Carlo Gambacorti‐Passerini, Aude Charbonnier, Andrea Viqueira, Eric Leip, (unknown), Erinn Hoag Goldman, Francis J. Giles, Thomas Ernst, Andreas Hochhaus, Gianantonio Rosti	1
2	High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMT 2024 ·ESMO Open ·Simona Secondino, Manuela Badoglio, Gianantonio Rosti, Myriam Labopin, Matthieu Delaye, Carsten Bokemeyer, Christoph Seidel, Edward Kanfer, Elisabetta Metafuni, Jürgen Finke, (unknown), Christos Kosmas, Florent Malard, Alessia Pagani, Jürgen Kuball, Ulrike Koehl, Annalisa Ruggeri, Ugo De Giorgi, Paolo Pedrazzoli	2
3	Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC. 2024 ·Journal of Clinical Oncology ·Michael W. Deininger, Jane Apperley, Christopher Arthur, Charles Chuah, Andreas Hochhaus, Hugues de Lavallade, Jeffrey H. Lipton, Elza Lomaia, James McCloskey, Lori J. Maness, Michael J. Mauro, Beatriz Moiraghi, Carolina Pavlovsky, Gianantonio Rosti, Philippe Rousselot, (unknown), Xiaowei Ren, Alexander Vorog, Hagop M. Kantarjian, Jörge E. Cortes	0
4	Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study 2023 ·Leukemia ·Gianantonio Rosti, Tim H. Brümmendorf, Bjørn Tore Gjertsen, (unknown), Fausto Castagnetti, Carlo Gambacorti‐Passerini, Thomas Ernst, (unknown), (unknown), (unknown), Francis J. Giles, Andreas Hochhaus	3
5	ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment 2023 ·International Journal of Molecular Sciences ·Maria Teresa Bochicchio, Giovanni Marconi, Carmen Baldazzi, (unknown), (unknown), Alessandro Lucchesi, Claudio Agostinelli, Elena Sabattini, (unknown), Anna Ferrari, (unknown), Chiara Servili, Andrea Ghelli Luserna di Rorà, Giovanni Martinelli, Giorgia Simonetti, Gianantonio Rosti	1
6	The use of granulocytic colony stimulating factors in patients receiving chemotherapy for germ cell tumors 2021 ·Simona Secondino, Andrea Ferrari, (unknown), (unknown), (unknown), Gianantonio Rosti	1
7	Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignancies 2019 ·Quality of Life Research ·Kathrin Sommer, Francesco Cottone, Neil K. Aaronson, Peter Fayers, Paola Fazi, Gianantonio Rosti, Emanuele Angelucci, Gianluca Gaïdano, Adriano Venditti, Maria Teresa Voso, Michele Baccarani, Marco Vignetti, Fabio Efficace	16
8	Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis 2017 ·Journal of Cancer Research and Clinical Oncology ·Andreas Hochhaus, (unknown), Philipp le Coutre, L. N. Petrov, Jeroen J. W. M. Janssen, Nicholas C.P. Cross, Delphine Réa, Fausto Castagnetti, Andrzej Hellmann, Gianantonio Rosti, Norbert Gattermann, (unknown), (unknown), Valentín García‐Gutiérrez, Bruno Vincenzi, Luca Dezzani, Francis J. Giles	6
9	TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 2014 ·Mediterranean Journal of Hematology and Infectious Diseases ·Michele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Gianantonio Rosti	31
10	Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors 2013 ·Expert Review of Hematology ·Gabriele Gugliotta, Fausto Castagnetti, Miriam Fogli, Michèle Cavo, Michele Baccarani, Gianantonio Rosti	18
11	Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib 2013 ·Leukemia ·(unknown), Delphine Réa, Michaela Schwarz, (unknown), Franck E. Nicolini, Gianantonio Rosti, Luciano Levato, Francis J. Giles, Hervé Dombret, Tristan Mirault, Hélène Labussière, Ruhdja Lindhorst, Wilhelm Haverkamp, Ivo Buschmann, Bernd Dörken, Phillipp D. Le Coutre	171
12	Evaluation of residual CD34⁺Ph⁺ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first‐line nilotinib therapy 2012 ·Cancer ·Marzia Defina, (unknown), Alessandro Gozzetti, Elisabetta Abruzzese, Fausto Castagnetti, (unknown), Mario Tiribelli, Massimo Breccia, Marzia Salvucci, (unknown), Claudia Baratè, Antonella Gozzini, Gianantonio Rosti, Francesco Lauria, Monica Bocchia	10
13	The response to imatinib and interferon- is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase 2010 ·Haematologica ·Francesca Palandri, Fabio Castagnetti, Ilaria Iacobucci, Giovanni Martinelli, Marilina Amabile, Gabriele Gugliotta, Antonio Poerio, Nicoletta Testoni, (unknown), (unknown), Monica Crugnola, Giovanna Rege‐Cambrin, B. Martino, Ivana Pierri, Franco Radaelli, Giorgina Specchia, Fabrizio Pane, Giuseppe Saglio, Gianantonio Rosti, Michele Baccarani	32
14	Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance. 2007 ·Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) ·Giovanni Martinelli, Ilaria Iacobucci, Simona Soverini, Francesca Palandri, Fausto Castagnetti, Gianantonio Rosti, Michele Baccarani	11
15	Does early stem-cell transplantation have a role in chronic myeloid leukaemia? 2005 ·The Lancet Oncology ·Aloïs Gratwohl, Gianantonio Rosti, Michele Baccarani	6
16	Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 2003 ·Blood ·Gianantonio Rosti, Giovanni Martinelli, Simona Bassi, Marilina Amabile, Elena Trabacchi, Barbara Giannini, Daniela Cilloni, Barbara Izzo, Antonio De Vivo, Nicoletta Testoni, Giovanna Rege Cambrin, Francesca Bonifazi, Simona Soverini, Simona Luatti, Enrico Gottardi, Daniele Alberti, Fabrizio Pane, Francesco Salvatore, Giuseppe Saglio, Michele Baccarani	56
17	Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia. 2001 ·PubMed ·Marilina Amabile, Barbara Giannini, Nicoletta Testoni, Vittorio Montefusco, Gianantonio Rosti, (unknown), Carolina Terragna, Silvia Buonamici, Emanuela Ottaviani, Simona Soverini, Mauro Fiacchini, Sebastián Bassi, Antonio De Vivo, Elena Trabacchi, Giuseppe Saglio, Fabrizio Pane, Michele Baccarani, S Tura, Giovanni Martinelli	36
18	Prognosis in patients with primary bone and/or bone marrow metastases(MET) of rhabdomyosarcoma (RMS). A joint report of the EBMT solid tumor working party and the German soft tissue sarcoma study (CWS). 1998 ·Bone Marrow Transplantation ·E. Koscielniak, Gianantonio Rosti, J. Treuner, O Hartmann, Ross Pinkerton, T. Klingebiel, Jean Michon, Ruth Ladenstein, Thierry Philip	0
19	In vitro amplification of hypervariable DNA regions for the evaluation of chimerism after allogeneic BMT. 1993 ·PubMed ·Giovanni Martinelli, (unknown), Alfonso Zaccaria, Patrizia Farabegoli, Marina Buzzi, Nicoletta Testoni, (unknown), Giuseppe Bandini, Gianantonio Rosti, A. Belardinelli	25
20	Ciclosporin A: Correlation of Blood Levels with Acute Graft-versus-Host Disease after Bone Marrow Transplantation 1987 ·Acta Haematologica ·Giuseppe Bandini, Enrico Strocchi, Paolo Ricci, Simonetta Rizzi, (unknown), (unknown), (unknown), Maria Rosa Motta, Valeria Giudice, Gianantonio Rosti, S Tura	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact